Lurbinectedin is a promising new drug used in the treatment of various types of cancer, particularly ovarian and small cell lung cancer. The drug is a synthetic analog of the marine compound trabectedin, and it works by targeting the transcription factor complex TFIIH, which is involved in the transcription and repair of DNA.

According to Drug Patent Watch [1], Lurbinectedin is currently being investigated in combination with other therapies, including doxorubicin, irinotecan, and temozolomide, in clinical trials. These trials are aimed at evaluating the safety and efficacy of Lurbinectedin when used in combination with other drugs.

One study published in the National Library of Medicine [2] found that Lurbinectedin in combination with doxorubicin showed significant antitumor activity in preclinical models of ovarian cancer. The study concluded that the combination of Lurbinectedin and doxorubicin could be a promising treatment option for patients with relapsed ovarian cancer.

Another study published in the National Cancer Institute [3] investigated the efficacy of Lurbinectedin in combination with cisplatin in patients with small cell lung cancer. The study found that the combination therapy showed promising results in terms of overall response rate and progression-free survival, with manageable toxicity.

In conclusion, Lurbinectedin shows promise as a treatment option for various types of cancer when used in combination with other therapies. Clinical trials are ongoing to evaluate the safety and efficacy of Lurbinectedin in combination with different drugs, and the results of these trials will provide valuable insights into the drug's potential as a cancer treatment.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900004/
[3] https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c82382